Anti-CD40CR MR1 antibody

Details Anti-CD40CR MR1 antibody Anti-CD40CR MR1 antibody

2005-05-10

2008-11-04

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S141100, C424S143100, C424S144100, C424S153100, C424S173100, C530S387100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750

Reexamination Certificate

active

07445781

ABSTRACT:
The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusion protein was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease.

REFERENCES:
patent: 5474771 (1995-12-01), Lederman
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5833987 (1998-11-01), Noelle et al.
patent: 0340604 (1989-11-01), None
patent: 0 555 880 (1993-08-01), None
patent: WO-96/23071 (1996-08-01), None
patent: WO-97/17446 (1997-05-01), None
patent: WO-98/30240 (1998-07-01), None
patent: WO-98/39026 (1998-09-01), None
patent: WO-99/00143 (1999-01-01), None
C. Mohan et al. “Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis,” Journal of Immunology, vol. 154, No. 3, 1995, pp. 1470-1480, XP002062342.
G. Early et al.: “Anti-CD40 Ligand Antibody Treatment Prevents the Development of Lupus-Like Nephritis in a Subset of New Zealand Black × New Zealand White Mice,” Journal of Immunology, vol. 157, No. 7, Oct. 1, 1996, pp. 3159-3164, XP002080042.
C. van Kooten et al.: “Functions of CD40 on B cells, dendritic cells and other cells,” Current Opinion in Immunology, Current Biology Ltd., vol. 9, No. 3, Jun. 1997, pp. 330-337, XP004313522.
Apr. 20, 2004 European Search Report.
Jun. 30, 2004 European Search Report.
Desai-Mehta, A., et al., “Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production”, Journal of Clinical Investigation, vol. 9, No. 97, May 1, 1996, pp. 2063-2073.
Noelle, Randolph J., et al., “A 39-kDa protein on activated helper T cells binds to CD40 and transduces the signal for cognate activation of B cells”, Proceedings of the National Academy of Sciences of USA, vol. 89, Jul. 1992, pp. 6550-6554.
Gray, David, et al., “Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction”, Journal of Experimental Medicine, vol. 180, No. 1, 1994, pp. 141-155.
C. Mohan et al.: “Interaction Between CD40 and its Ligand gp39 in the Development of murine Lupus Nephritis,” Journal of Immunology, vol. 154, No. 3, 1995, pp. 1470-1480, XP002062342.
A. Desai-Mehta et al.: “Hypertension of CD40 Ligand by B and T Cells in Human Lupus and its Role in Pathogenic Autoantibody Production,” Journal of Clinical Investigation, vol. 9, No. 97, May 1, 1996, pp. 2063-2073, XP002080040.
Partial European Search Report.
Clark, “CD40: A Cytokine Receptor in Search of a Ligand.” Tissue Antigens, 1990, vol. 35, pp. 33-36.

Affiliated with

Also associated with

Rating

Anti-CD40CR MR1 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-CD40CR MR1 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD40CR MR1 antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4038797